House committee narrows Rare Disease Advisory Council membership; caregiver urges council to address isolation and system navigation

The House Human Services Committee moved a set of membership and drafting changes while marking up a bill to create a Rare Disease Advisory Council (RDAC), and heard testimony from a caregiver and genetic navigator who urged the panel to address family isolation, care coordination and coverage gaps.

Committee members agreed by discussion—not recorded as a roll-call vote—to reduce and reconfigure the council's membership list, remove language that allowed a single person to fill multiple membership roles, and delete a backup subdivision intended to add a gubernatorial appointee if the council had an even number of members. After deliberation the committee settled on an 11‑member advisory body that includes: a Department of Health representative; one member of the Health Equity Advisory Commission (selected by that commission); two individuals with lived experience of rare disease; one representative of academic rare‑disease research; one parent or guardian of a person living with a rare disease; a practicing physician and a practicing nurse; a geneticist or genetic counselor; a pharmacist; and a representative ("Dale" in the transcript) who provides services to people with rare conditions. The committee also added explicit language enabling the RDAC to collaborate with national organizations, naming the National Organization for Rare Disorders (NORD) as an example.

"I think one of the biggest challenges of living with a rare disease is the isolation that comes from it and not being visible to the world," testified Ashley Michaud, who identified herself as a caregiver for a daughter with multiple rare, congenital and genetic conditions and as genetic navigator for Vermont Family Network. Michaud told the committee she and many Vermont families face long travel for specialty care, inconsistent local services, repeated administrative burdens for Medicaid waivers (Katie Beckett), and high out‑of‑pocket pharmaceutical costs. She said the state's designated agency rules excluded her daughter from certain supports because the child's condition did not match the agency's developmental‑delay criteria.

Michaud described a multi-year, multi-condition diagnostic and care pathway: newborn screens that briefly suggested cystic fibrosis; early developmental delays and a magnetic resonance imaging result consistent with Joubert syndrome; vision delays; complex airway problems that required surgery and led to prolonged hospitalizations; a G‑tube for feeding; and subsequent immunology work that identified severe T‑cell and B‑cell abnormalities. She said the family obtained whole‑genome sequencing but still lacks a single unifying diagnostic label for one of her daughter's immune conditions. Michaud said care requires frequent travel to Boston for specialty visits, and that certain biologic infusions used for immune support can cost "probably roughly about $5,000 a week," which the family currently manages with insurance and Medicaid supports.

Committee members pressed staff about membership balance, appointing authorities, and whether the council should require members to be practicing in Vermont. Members also debated whether caregivers should be described as "parent or guardian" (the panel reached consensus to include parent or guardian) and how to ensure the council represents both pediatric and adult rare‑disease perspectives. The group discussed appointment sources: the draft specified the speaker of the House and the Senate Committee on Committees would make certain appointments; the committee kept that approach but adjusted which positions each appointing authority would fill.

On powers and duties, committee members questioned the feasibility of a single needs assessment that attempted to cover hundreds of different rare diseases. Members and the witness suggested the RDAC should identify common system gaps—transportation barriers, pharmacy and high-cost drug access, case management and care coordination shortfalls, respite and education supports—and recommend targeted remedies rather than attempting an exhaustive, disease‑by‑disease evaluation.

Witnesses and members identified several potential deliverables for the RDAC: a statewide needs assessment of service and access gaps (by common system need rather than by every specific diagnosis), recommendations on case management or complex‑care coordination, proposals to reduce administrative burdens for Medicaid waivers (Katie Beckett), and strategies to expand access to qualified respite and school supports. Committee members discussed whether University of Vermont Medical Center (UVM) would host or house the advisory council but did not finalize placement; they reported outreach to UVM to determine interest.

Committee members temporarily suspended the markup to hear additional witnesses and planned to resume further changes after the break. No formal roll‑call votes were recorded in the session minutes provided.